Group 1 - The core viewpoint of the article is that China Tongfu (01763) issued a profit warning, leading to a decline of over 7% in its stock price, which was reported at 20.3 HKD with a trading volume of 11.47 million HKD [1] - The company expects annual revenue to be approximately 6.979 billion to 7.206 billion RMB, representing a year-on-year decrease of about 5% to 8% [1] - Net profit is projected to be around 611 million to 655 million RMB, indicating a year-on-year decline of approximately 25% to 30% [1] Group 2 - Profit attributable to equity shareholders is expected to be between 302 million to 322 million RMB, reflecting a year-on-year decrease of about 20% to 25% [1] - The announcement states that the company's operations are currently normal, and the revenue decline for the fiscal year 2025 is primarily due to a decrease in revenue from the nuclear medical equipment segment [1] - The profit reduction is mainly attributed to tax payments and late fees incurred by the company's subsidiary, Shenzhen Zhonghe Haidewei Biotechnology Co., Ltd. [1]
中国同辐盈警后跌超7% 预计去年纯利跌最多25% 收入下滑最多8%